The U.S. FDA delayed its decision on Orca Bio’s T cell therapy, pushing the deadline three months to July 6 after the company filed additional manufacturing information. The original timeline expected a verdict by April 6, but the agency moved the review window as Orca submitted updated manufacturing data in response to FDA requests. This is a key inflection point for the program because manufacturing readiness is typically one of the hardest bottlenecks in cell-therapy development, and timing changes can affect investors’ outlook and trial-planning synchronization. Orca indicated the filing update was related to manufacturing and chemistry, manufacturing, and controls (CMC) requirements rather than a safety signal. Still, the delay keeps the program’s regulatory milestone in focus and extends the window for final readiness checks. For developers and CDMOs alike, the episode reinforces how CMC updates can drive regulatory schedule changes—especially for complex, autologous or engineered T-cell constructs.